U.S. Department of Commerce FORM PTO-1618A Patent and Trademark Office Expires 06/30/99 **IRADEMARK** 07-23-1999 101098698 R SHEET TRADEMARKS ONLY TO: The Commissioner of Patents and Trademarks: Please record the attached original document(s) or copy(ies) Submission Type Conveyance Type X License New **Assignment** (Non-Recordation) Resubmission **Security Agreement Nunc Pro Tunc Assignment** Document ID # **Effective Date** Month Day Year Merger **Correction of PTO Error** Reel # Frame # Change of Name **Corrective Document** Reel # Frame # Other Conveying Party Mark if additional names of conveying parties attached **Execution Date** Month Day Year Name Gamera Bioscience Corporation 28 99 Formerly . Individual General Partnership Limited Partnership | X | Corporation **Association** Other Citizenship/State of Incorporation/Organization Receiving Party Mark if additional names of receiving parties attached Name Silicon Valley Bank DBA/AKA/TA Composed of 3003 Tasman Drive Address (line 1) Address (line 2) Address (line 3) Santa Clara CA 95054 State/Country Zip Code If document to be recorded is an Individual General Partnership **Limited Partnership** assignment and the receiving party is not domiciled in the United States, an Corporation **Association** appointment of a domestic representative should be attached. Other (Designation must be a separate document from Assignment.) Citizenship/State of Incorporation/Organization CA FOR OFFICE USE ONLY 07/22/1999 DNGUYEN 00000173 75345185 FC:481 FC:482 200.00 DP

Public burden reporting for this collection of information is estimated to average approximately 30 minutes per Cover Sheet to be recorded, including time for reviewing the document and gathering the data needed to complete the Cover Sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Chief Information Officer, Washington, D.C. 20231 and to the Office of Information and Regulatory Affairs, Office of Management and Budget, Paperwork Reduction Project (0651-0027), Washington, D.C. 20503. See OMB Information Collection Budget Package 0651-0027, Patent and Trademark Assignment Practice. DO NOT SEND REQUESTS TO RECORD ASSIGNMENT DOCUMENTS TO THIS ADDRESS.

FORM PTO- Expires 08/30/99 OMB 0851-0027	618B	Page 2	U.S. Department of Commerce Patent and Trademark Office TRADEMARK
Domestic R	epresentative Name and Addr	ess Enter for the first R	eceiving Party only.
Name			
Address (line 1)			
Address (line 2)			
Address (line 3)			
Address (line 4)			
Correspond	ent Name and Address Area Co	ode and Telephone Number	703-415-1555
Name	Christopher E. Kondracki		
Address (line 1)	2001 Jefferson Davis Hwy.		
Address (line 2)	Suite 505		
Address (line 3)			
Address (line 4)	Arlington, VA 22202		
Pages	Enter the total number of pages of including any attachments.	the attached conveyance do	cument # 14
Trademark /	application Number(s) or Regi	stration Number(s)	Mark if additional numbers attached
	Trademark Application Number or the Regist		• •
r	emark Application Number(s)		ration Number(s)
75/345,18	75/345,186 75/345,18	37. [] [
75/345,18	75/345,189 75/345,19	00	
75/345,19	75/521,722 75/521,40		
Number of F	roperties Enter the total numb	er of properties involved.	# 9
Fee Amount	Fee Amount for Prop	erties Listed (37 CFR 3.41):	\$ 240.00
Method of		Deposit Account	7 210,00
Deposit A (Enter for pa	yment by deposit account or if additional fee	s can be charged to the account.) ccount Number:	# 19-3545
	Authoriza	tion to charge additional fees:	Ves X No

Statement and Signature

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. Charges to deposit account are authorized, as indicated herein.

Hidicated Hereni.

Name of Person Signing	Signature
Christopher E. Kondracki	Chile

July 9, 1999

Signature Date Signed

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement (this "IP Agreement") is made as of the day of May, 1999 by and between Gamera Bioscience Corporation ("Grantor"), and Silicon Valley Bank, a California banking corporation ("Lender").

RECITALS

- A. Lender has agreed to make advances of money and to extend certain financial accommodations to Grantor (the "Loans"), pursuant to a Loan and Security Agreement dated September 9, 1998 (the "Loan Agreement") and Grantor desires to borrow such funds from Lender. The Loan is or will be secured in part pursuant to the terms of the Loan Agreement. Lender is willing to make such Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Lender a security interest in certain Copyrights Trademarks, Patents, and Mask Works to secure the obligations of Grantor under the Loan Agreement. Defined terms used but not defined herein shall have the same meanings as in the Loan Agreement.
- B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Lender a security interest in all of Grantor's right title and interest, whether presently existing or hereafter acquired in, to and under all of the Collateral (as defined herein).
- NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged and intending to be legally bound, as collateral security for the prompt and complete payment when due of Grantor's Indebtedness under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:
- 1. <u>Grant of Security Interest.</u> As collateral security for the prompt and complete payment and performance of all of Grantor's present or future Indebtedness, obligations and liabilities to Lender, Grantor hereby grants a security interest in all of Grantor's right, title and interest in, to and under its Intellectual Property Collateral (all of which shall collectively be called the "Intellectual Property Collateral"), including, without limitation, the following:
 - (a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the "Copyrights");
 - (b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;
 - (c) Any and all design rights which may be available to Grantor now or hereafter existing, created, acquired or held;
 - (d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");
 - (e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the "Trademarks")

- (f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the "Mask Works");
- (g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;
- (h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights; and
- (i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and
- (i) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.
- 2. <u>Authorization and Request.</u> Grantor authorizes and requests that the Register of Copyrights and the Commissioner of Patents and Trademarks record this IP Agreement.
 - 3. <u>Covenants and Warranties.</u> Grantor represents, warrants, covenants and agrees as follows:
 - (a) Grantor is now the sole owner of the Intellectual Property Collateral, except for non-exclusive licenses granted by Grantor to its customers in the ordinary course of business.
 - (b) Performance of this IP Agreement does not conflict with or result in a breach of any IP Agreement to which Grantor is bound, except to the extent that certain intellectual property agreements prohibit the assignment of the rights thereunder to a third party without the licensor's or other party's consent and this IP Agreement constitutes a security interest.
 - (c) During the term of this IP Agreement, Grantor will not transfer or otherwise encumber any interest in the Intellectual Property Collateral, except for non-exclusive licenses granted by Grantor in the ordinary course of business or as set forth in this IP Agreement;
 - (d) To its knowledge, each of the Patents is valid and enforceable, and no part of the Intellectual Property Collateral has been judged invalid or unenforceable, in whole or in part, and no claim has been made that any part of the Intellectual Property Collateral violates the rights of any third party;
 - (e) Grantor shall promptly advise Lender of any material adverse change in the composition of the Collateral, including but not limited to any subsequent ownership right of the Grantor in or to any Trademark, Patent, Copyright, or Mask Work specified in this IP Agreement;
 - (f) Grantor shall (i) protect, defend and maintain the validity and enforceability of the Trademarks, Patents, Copyrights, and Mask Works, (ii) use its best efforts to detect infringements of the Trademarks, Patents, Copyrights, and Mask Works and promptly advise Lender in writing of material infringements detected and (iii) not allow any Trademarks, Patents, Copyrights, or Mask Works to be abandoned, forfeited or dedicated to the public without the written consent of Lender, which shall not be unreasonably withheld, unless Grantor determines that reasonable business practices suggest that abandonment is appropriate.
 - (g) Grantor shall promptly register the most recent version of any of Grantor's Copyrights, if not so already registered, and shall, from time to time, execute and file such other instruments, and take

such further actions as Lender may reasonably request from time to time to perfect or continue the perfection of Lender's interest in the Intellectual Property Collateral;

- (h) This IP Agreement creates, and in the case of after acquired Intellectual Property Collateral, this IP Agreement will create at the time Grantor first has rights in such after acquired Intellectual Property Collateral, in favor of Lender a valid and perfected first priority security interest in the Intellectual Property Collateral in the United States securing the payment and performance of the obligations evidenced by the Loan Agreement upon making the filings referred to in clause (i) below;
- (i) To its knowledge, except for, and upon, the filing with the United States Patent and Trademark office with respect to the Patents and Trademarks and the Register of Copyrights with respect to the Copyrights and Mask Works necessary to perfect the security interests created hereunder and except as has been already made or obtained, no authorization, approval or other action by, and no notice to or filing with, any U.S. governmental authority or U.S. regulatory body is required either (i) for the grant by Grantor of the security interest granted hereby or for the execution, delivery or performance of this IP Agreement by Grantor in the U.S. or (ii) for the perfection in the United States or the exercise by Lender of its rights and remedies thereunder;
- (j) All information heretofore, herein or hereafter supplied to Lender by or on behalf of Grantor with respect to the Intellectual Property Collateral is accurate and complete in all material respects.
- (k) Grantor shall not enter into any agreement that would materially impair or conflict with Grantor's obligations hereunder without Lender's prior written consent, which consent shall not be unreasonably withheld. Grantor shall not permit the inclusion in any material contract to which it becomes a party of any provisions that could or might in any way prevent the creation of a security interest in Grantor's rights and interest in any property included within the definition of the Intellectual property Collateral acquired under such contracts, except that certain contracts may contain anti-assignment provisions that could in effect prohibit the creation of a security interest in such contracts.
- (I) Upon any executive officer of Grantor obtaining actual knowledge thereof, Grantor will promptly notify Lender in writing of any event that materially adversely affects the value of any material Intellectual Property Collateral, the ability of Grantor to dispose of any material Intellectual Property Collateral of the rights and remedies of Lender in relation thereto, including the levy of any legal process against any of the Intellectual Property Collateral.
- 4. <u>Lender's Rights.</u> Lender shall have the right, but not the obligation, to take, at Grantor's sole expense, any actions that Grantor is required under this IP Agreement to take but which Grantor fails to take, after fifteen (15) days' notice to Grantor. Grantor shall reimburse and indemnify Lender for all reasonable costs and reasonable expenses incurred in the reasonable exercise of its rights under this section 4.
- 5. Inspection Rights. Grantor hereby grants to Lender and its employees, representatives and agents the right to visit, during reasonable hours upon prior reasonable written notice to Grantor, any of Grantor's plants and facilities that manufacture, install or store products (or that have done so during the prior six-month period) that are sold utilizing any of the Intellectual Property Collateral, and to inspect the products and quality control records relating thereto upon reasonable written notice to Grantor and as often as may be reasonably requested, but not more than once in every six (6) months; provided, however, nothing herein shall entitle Lender access to Grantor's trade secrets and other proprietary information.

6. Further Assurances: Attorney in Fact.

(a) On a continuing basis, Grantor will, subject to any prior licenses, encumbrances and restrictions and prospective licenses, make, execute, acknowledge and deliver, and file and record in the proper filing and recording places in the United States, all such instruments, including appropriate financing and continuation

statements and collateral agreements and filings with the United States Patent and Trademarks Office and the Register of Copyrights, and take all such action as may reasonably be deemed necessary or advisable, or as requested by Lender, to perfect Lender's security interest in all Copyrights, Patents, Trademarks, and Mask Works and otherwise to carry out the intent and purposes of this IP Agreement, or for assuring and confirming to Lender the grant or perfection of a security interest in all Intellectual Property Collateral.

- (b) Grantor hereby irrevocably appoints Lender as Grantor's attorney-in-fact, with full authority in the place and stead of Grantor and in the name of Grantor, Lender or otherwise, from time to time in Lender's discretion, upon Grantor's failure or inability to do so, to take any action and to execute any instrument which Lender may deem necessary or advisable to accomplish the purposes of this IP Agreement, including:
 - (i) To modify, in its sole discretion, this IP Agreement without first obtaining Grantor's approval of or signature to such modification by amending Exhibit A, Exhibit B, Exhibit C, and Exhibit D hereof, as appropriate, to include reference to any right, title or interest in any Copyrights, Patents, Trademarks or Mask Works acquired by Grantor after the execution hereof or to delete any reference to any right, title or interest in any Copyrights, Patents, Trademarks, or Mask Works in which Grantor no longer has or claims any right, title or interest; and
 - (ii) To file, in its sole discretion, one or more financing or continuation statements and amendments thereto, relative to any of the Intellectual Property Collateral without the signature of Grantor where permitted by law.
- 7. <u>Events of Default.</u> The occurrence of any of the following shall constitute an Event of Default under this IP Agreement:
 - (a) An Event of Default occurs under the Loan Agreement; or any document from Grantor to Lender; or
 - (b) Grantor breaches any warranty or agreement made by Grantor in this IP Agreement.
- Remedies. Upon the occurrence and continuance of an Event of Default, Lender shall have the right to exercise all the remedies of a secured party under the Massachusetts Uniform Commercial Code, including without limitation the right to require Grantor to assemble the Intellectual Property Collateral and any tangible property in which Lender has a security interest and to make it available to Lender at a place designated by Lender. Lender shall have a nonexclusive, royalty free license to use the Copyrights, Patents, Trademarks, and Mask Works to the extent reasonably necessary to permit Lender to exercise its rights and remedies upon the occurrence of an Event of Default. Grantor will pay any expenses (including reasonable attorney's fees) incurred by Lender in connection with the exercise of any of Lender's rights hereunder, including without limitation any expense incurred in disposing of the Intellectual Property Collateral. All of Lender's rights and remedies with respect to the Intellectual Property Collateral shall be cumulative.
- 9. <u>Indemnity.</u> Grantor agrees to defend, indemnify and hold harmless Lender and its officers, employees, and agents against: (a) all obligations, demands, claims, and liabilities claimed or asserted by any other party in connection with the transactions contemplated by this IP Agreement, and (b) all losses or expenses in any way suffered, incurred, or paid by Lender as a result of or in any way arising out of, following or consequential to transactions between Lender and Grantor, whether under this IP Agreement or otherwise (including without limitation, reasonable attorneys fees and reasonable expenses), except for losses arising from or out of Lender's gross negligence or willful misconduct.
- 10. <u>Reassignment.</u> At such time as Grantor shall completely satisfy all of the obligations secured hereunder, Lender shall execute and deliver to Grantor all deeds, assignments, and other instruments as may be necessary or proper to reinvest in Grantor full title to the property assigned hereunder, subject to any disposition thereof which may have been made by Lender pursuant hereto.

- 11. <u>Course of Dealing.</u> No course of dealing, nor any failure to exercise, nor any delay in exercising any right, power or privilege hereunder shall operate as a waiver thereof.
- 12. <u>Attorneys' Fees.</u> If any action relating to this IP Agreement is brought by either party hereto against the other party, the prevailing party shall be entitled to recover reasonable attorneys fees, costs and disbursements.
- 13. Amendments. This IP Agreement may be amended only by a written instrument signed by both parties hereto.
- 14. <u>Counterparts.</u> This IP Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute the same instrument.
- 15. <u>Law and Jurisdiction</u>. This IP Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts. GRANTOR ACCEPTS FOR ITSELF AND IN CONNECTION WITH ITS PROPERTIES, UNCONDITIONALLY, THE NON-EXCLUSIVE JURISDICTION OF ANY STATE OR FEDERAL COURT OF COMPETENT JURISDICTION IN THE COMMONWEALTH OF MASSACHUSETTS IN ANY ACTION, SUIT, OR PROCEEDING OF ANY KIND, AGAINST IT WHICH ARISES OUT OF OR BY REASON OF THE AGREEMENT; PROVIDED, HOWEVER, THAT IF FOR ANY REASON LENDER CANNOT AVAIL ITSELF OF THE COURTS OF THE COMMONWEALTH OF MASSACHUSETTS, GRANTOR ACCEPTS JURISDICTION OF THE COURTS AND VENUE IN SANTA CLARA COUNTY, CALIFORNIA.

GRANTOR AND LENDER EACH HEREBY WAIVE THEIR RESPECTIVE RIGHTSTO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF ANY OF THE LOAN DOCUMENTSOR ANY OF THE TRANSACTIONS CONTEMPLATED THEREIN, INCLUDING CONTRACT CLAIMS, TORT CLAIMS BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW OR STATUTORY CLAIMS. EACH PARTY RECOGNIZES AND AGREES THAT THE FOREGOING WAIVER CONSTITUTES A MATERIAL INDUCEMENT FOR IT TO ENTER INTO THIS AGREEMENT. EACH PARTY REPRESENTS AND WARRANTS THAT IT HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL AND THAT IT KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.

16. <u>Confidentiality.</u> In handling any confidential information, Lender shall exercise the same degree of care that it exercises with respect to its own proprietary information of the same types to maintain the confidentiality of any non-public information thereby received or received pursuant to this !P Agreement except that the disclosure of this information may be made (i) to the affiliates of the Lender, (ii) to prospective transferee or purchasers of an interest in the obligations secured hereby, provided that they have entered into comparable confidentiality agreement in favor of Grantor and have deliver a copy to Grantor, (iii) as required by law, regulation, rule or order, subpoena judicial order or similar order and (iv) as may be required in connection with the examination, audit or similar investigation of Lender.

EXECUTED as a sealed instrument th Massachusetts.	is 28 day of May, 1999 under the laws of the Commonwealth of
Address of Grantor:	GRANTOR:
200 Boston Avenue	Gamera Bioscience Corporation
Medford, Massachusetts 02155	By: Dunft, M. Lunger
	Name: DOAN H. MCAUSAND Title: VP FINANCE/CORP. Developm

Exhibit "B" attached to that certain Intellectual Property Security Agreement dated May 28, 1999.

EXHIBIT "B"

PATENTS

PATENT
DESCRIPTION
DATE STATUS

DOCKET NO.

COUNTRY SERIAL NO.

FILING

Case No.	Serial No.	Status/Country	Patent No.	Date	Technology
93,407-B	08/353,573	Issued/US	5,686,271	11/11/97	MCR/Apparatus
93,407-C	08/375,226	Issued/US	5,545,540	8/13/96	MCR/method
93,407-D	71067/94	Issued/AU	690,124	86/9/8	MCR/Method
93,407-E	2,164,706	Pending/CA		6/8/94	MCR/Method
93,407-F	94920180.0	National/EPC		6/8/94	MCR/Method
93,407-G	7-502156	Pending/JP		6/8/94	MCR/Method
93,407-H	PCT 705633/95	Pending/SK		6/8/94	MCR/Method
93,407-J	45175/96	Issued/AU	691,076	8/20/98	MCR/Apparatus
93,407-K	2,207,388	Pending/CA		12/5/95	MCR/Apparatus
93,407-L	95197573.0	Pending CN		12/5/95	MCR/Apparatus
93,407-M	95943789.8	Allowed/EPC		12/5/95	MCR/Apparatus
93,407-N	517831/1996	Pending/JP		12/5/95	MCR/Apparatus
93,407-O	PCT 703828/97	Pending/SK		12/5/95	MCR/Apparatus
94,179	08/218,030	Abandoned/US		3/24/94	SPS/Method
94,179-B	08/464,081	Issued/US	5,683,657	11/4/97	SPS/Apparatus
94,179-C	21281/95	Issued/AU	909,606	12/3/98	SPS
94,179-D	2,186,340	Pending/CA		3/24/95	SPS
94,179-E	95193250.0	Pending/CN		3/24/95	SPS
94,179-F	95914181.3	Pending/EPC		3/24/95	SPS

Case No.	Serial No.	Status/Country	Patent No.	Date	Technology
94,179-G	52438195	Pending/JP		3/24/95	SPS
94,179-H	705448/96	Pending/SK		3/24/95	SPS
95,1408-D	08/761,063	Pending/US		12/5/96	LABCD
95,1408-E	PCT/US96/19514	National/PCT		12/5/96	LABCD
95,1408-G	08/768,990	Pending/US		12/18/96	LABCD
95,1408-H	60/047,488	Prov./US		5/22/98	LABCD
95,1408-I	08/910,726	Pending/US		8/12/97	Passive valves
95,1408-J	PCT/US97/11585	National/PCT		8/12/97	Passive valves
95,1408-K	950,566/80	Pending/US		12/19/97	Cell counting
95,1408-L	PCT/US97/22264	Pending/PCT		12/19/97	Cell counting
95,1408-M	60/078,834	Abandoned/US		3/19/99	LABCD
95,1408-N	To be assigned	Pending/US		5/19/99	Analyte Detection
95,1408-O	9085,306	Abandoned/US		5/13/98	LABCD
95,1408-P	09/083,678	Allowed/US		5/22/98	LABCD
95,1408-Q	PCT/US98/10520	Pending/PCT		5/22/98	LABCD
95,1408-R	702,403	Pending/AU		12/5/96	LABCD
95,1408-S	2,239,613	Pending/CA		12/5/96	LABCD
95,1408-T	96196871.7	Pending/CN		12/5/96	LABCD
95,1408-U	96943641.9	Pending/EPC		12/5/96	LABCD

95,1408-V	9-521481	Pending/JP	12/5/96	LABCD
95,1408-W	984463	Pending/MX	12/5/96	LABCD
95,1408-X	P982563	Pending/NO	12/5/96	LABCD
95,1408-Y	704305/98	Pending/SK	12/5/96	LABCD
95,1408-Z	To be assigned	Pending/CA	12/5/95	LABCD
95,1408-AA	97939336.0	Pending/EPC	8/12/97	Passive valves
95,1408-BB	195,09702	Pending/JP	8/12/97	Passive valves
95,1408-MM	60/143,086	Prov/US	5/14/99	PCR

Issue date for granted patents, allowance date for allowed patents, filing date for pending U.S. applications, and the anniversary date for U.S. provisional applications, and the publication date for foreign patent applications H

Date

Chris

Exhibit "C" attached to that certain Intellectual Property Security Agreement dated May 26, 1999.

EXHIBIT "C"

TRADEMARKS

TRADEMARK

<u>DESCRIPTION</u> <u>COUNTRY</u> <u>SERIAL NO.</u>

REG. NO

STATUS

TRADEMARKS

•				
	Case No.	Serial No.	Status	Trademark
_	97,415	75/345185	Pending; response due 11/4/98	GAMERA BIOSCIENCE
<u>n</u>	97,416	75/345186	Pending; response due 11/4/98	LABCD
3)	97,417	75/345187	Pending; response due 11/4/98	CDLAB
4	97,418	75/345188	Pending; response due 11/4/98	LAB ON A CD
1	97,419	75/345189	Pending; response due 10/28/98	LAB ON A DISC
70	97,420	75/345190	Pending , , $10/\nu L/98$	BIODISC
1	97,421	75/345191	Pending; response due 10/28/98	BIOCD
5				
00		75-521,72a	Fending (Filed 7/20/AR)	CEU CD
6		10th les-sh	Fending (Filed 7/30/98)	LAB DVD
	-			